Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Notes Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Cyclacel Pharmaceuticals Notes Receivable?

Cyclacel Pharmaceuticals's Notes Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Cyclacel Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Notes Receivable Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Notes Receivable

Get a 7-Day Free Trial

Cyclacel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Cyclacel Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Cyclacel Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

CYCCP.PFD:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Executives

Spiro Rombotis	director, officer: President & C.E.O.	C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron	director, officer: E.V.P., Finance & C.O.O.	C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson	director	2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker	director	51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker	director	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum	officer: Chief Medical Officer	66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd	10 percent owner	10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd.	10 percent owner	10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart	10 percent owner	P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems	director	C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017